In an ongoing and open collaboration between iNovacia AB, GE Healthcare, Sweden and scientists at the Department of Medical Biochemistry and Biophysics (MBB) at Karolinska Institutet, the surface plasmon resonance and nuclear magnetic resonance techniques have been cross-validated as fragment screening techniques.
iNovacia, an international contract research company owned by Kancera AB, announces the first results from a collaboration in which the iNovacia fragment collection–consisting of roughly 1,000 highly soluble, diverse and low-molecular-weight chemical scaffolds–has been used to cross-validate two biophysical techniques as fragment screening techniques. PARP15, a putative drug target, was used as target protein.
The iNovacia fragment collection has been screened for binding against PARP15 by surface plasmon resonance (Biacore T200) at GE Healthcare and 14 out 15 fragment binders were possible to confirm by nuclear magnetic resonance (NMR) methods at iNovacia. The PARP15 protein was produced at MBB. The structures of the confirmed hits will be published.
Thomas Olin, CEO of iNovacia and Kancera, comments: “The collaboration with GE Healthcare and MBB has been highly productive, so far resulting in a technical cross-validation valuable both for GE Healthcare and iNovacia. In addition, the high quality of iNovacia´s fragment collection has yet again been confirmed”.
Date: December 8, 2011
Source: www.kancera.com/ Kancera AB
